Fisher & Paykel Healthcare Company Restricted (OTCPK:FSPKF) Q2 2026 Earnings Name November 25, 2025 4:00 PM EST
Firm Contributors
Marcus Driller – Vice President of Company
Lewis Gradon – MD, CEO & Govt Director
Lyndal York – Chief Monetary Officer
Justin Callahan – VP of Gross sales & Advertising and marketing
Convention Name Contributors
Lyanne Harrison – BofA Securities, Analysis Division
Dan Hurren – MST Monetary Companies Pty Restricted, Analysis Division
Stephen Ridgewell – Craigs Funding Companions Restricted, Analysis Division
Davinthra Thillainathan – Goldman Sachs Group, Inc., Analysis Division
Vanessa Thomson – Jefferies LLC, Analysis Division
Matt Montgomerie – Forsyth Barr Group Ltd., Analysis Division
Craig Wong-Pan – RBC Capital Markets, Analysis Division
Saul Hadassin – Barrenjoey Markets Pty Restricted, Analysis Division
Marcus Curley – UBS Funding Financial institution, Analysis Division
Andrew Paine – CLSA Restricted, Analysis Division
Adrian Allbon – Jarden Restricted, Analysis Division
David Bailey – Morgan Stanley, Analysis Division
Christine Trinh – Macquarie Analysis
Presentation
Operator
Welcome to Fisher & Paykel Healthcare’s Outcomes Convention Name. My identify is Lisa, and I will be your operator for immediately’s name. [Operator Instructions] Please be aware, this convention name is being recorded. I would now like to show the decision over to Marcus Driller, VP Company.
Marcus Driller
Vice President of Company
Thanks, Lisa. Properly, good morning, everybody, and welcome to the convention name for Fisher & Paykel Healthcare’s First Half Outcomes for the 2026 monetary 12 months. On the decision immediately are Lewis Gradon, Managing Director and Chief Govt Officer; Lyndal York, Chief Monetary Officer; Andy Niccol, Chief Working Officer; Justin Callahan, VP, Gross sales and Advertising and marketing; and Andrew Somervell, VP of Merchandise and Know-how. Lewis and Lyndal will first present an outline of the outcomes, after which we’ll transfer on to questions. We’ll be discussing our outcomes for the 6 months ended 30 September 2025. Earlier immediately, we offered our 2026 interim report, together with monetary statements and commentary on our outcomes to the NZX and ASX. These disclosures may be accessed on our web site. With that, I would now like to show the decision over to Lewis.
